Mutual of America Capital Management LLC Sells 3,144 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Mutual of America Capital Management LLC lowered its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 397,772 shares of the medical equipment provider’s stock after selling 3,144 shares during the quarter. Mutual of America Capital Management LLC’s holdings in BioLife Solutions were worth $9,960,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Louisiana State Employees Retirement System increased its holdings in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after acquiring an additional 700 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after buying an additional 753 shares in the last quarter. Sei Investments Co. boosted its stake in BioLife Solutions by 1.4% during the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after buying an additional 839 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 1,374 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Northland Securities upped their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright initiated coverage on shares of BioLife Solutions in a report on Monday, September 30th. They issued a “buy” rating and a $29.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.83.

Insider Activity

In related news, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. This trade represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,471 shares of company stock valued at $656,330. 2.20% of the stock is currently owned by company insiders.

BioLife Solutions Stock Down 2.9 %

Shares of BLFS opened at $21.02 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $24.00 and a 200 day moving average of $22.82. The company has a market cap of $975.12 million, a PE ratio of -19.83 and a beta of 1.88. BioLife Solutions, Inc. has a 52-week low of $11.40 and a 52-week high of $28.88.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.